Last $59.96 USD
Change Today -0.17 / -0.28%
Volume 1.2M
STJ On Other Exchanges
New York
As of 1:55 PM 10/1/14 All times are local (Market data is delayed by at least 15 minutes).

st jude medical inc (STJ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/7/14 - $71.90
52 Week Low
10/1/13 - $53.48
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ST JUDE MEDICAL INC (STJ)

st jude medical inc (STJ) Related Businessweek News

View More BusinessWeek News

st jude medical inc (STJ) Details

St. Jude Medical, Inc. develops, manufactures and distributes medical devices for cardiac rhythm management, cardiovascular, and atrial fibrillation therapy areas worldwide. It operates in two divisions, Implantable Electronic Systems, and Cardiovascular and Ablation Technologies. The company offers tachycardia implantable cardioverter defibrillator systems that provide therapy to patients suffering from heart conditions, such as sudden cardiac arrest; and cardiac resynchronization therapy devices to treat patients suffering from heart failure. It also provides pacemakers for patients whose hearts beat too slowly or who suffer from other cardiac arrhythmias; leads to carry electrical impulses to the heart and provide information from the heart to the device; and programmers and remote monitoring equipment, which are used by physicians and healthcare professionals to program cardiac rhythm management devices and analyze device data to enhance patient management. In addition, the company offers vascular closure devices, compression assist devices, pressure measurement guidewires, diagnostic coronary imaging technology, vascular plugs, percutaneous catheter introducers, and diagnostic guidewires; and transcatheter aortic heart valves, heart valve repair and replacement products, and transcatheter structural heart defect devices. Further, it provides electrophysiology introducers and catheters, and ablation systems, as well as cardiac mapping, navigation, and recording systems for diagnosing and treating various irregular heart rhythms. Additionally, the company offers neurostimulation systems for chronic pain, such as rechargeable and primary cell implantable pulse generators. The company sells its products through direct sales force and independent distributors. St. Jude Medical, Inc. was founded in 1976 and is headquartered in Saint Paul, Minnesota.

16,000 Employees
Last Reported Date: 02/26/14
Founded in 1976

st jude medical inc (STJ) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.0M
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $430.0K
Chief Operating Officer
Total Annual Compensation: $730.0K
President of International Division
Total Annual Compensation: $752.4K
Executive Vice President
Total Annual Compensation: $730.0K
Compensation as of Fiscal Year 2013.

st jude medical inc (STJ) Key Developments

St. Jude Medical, Inc. Launches OPTIS Integrated System

St. Jude Medical Inc. announced the company has secured CE Mark and FDA clearance for the new OPTIS(TM) Integrated System. The system is a departure from traditional, mobile cart-based diagnostic tools and advances percutaneous coronary intervention (PCI) optimization via direct installation into a hospital's cardiac catheterization laboratory, fully integrating optical coherence tomography (OCT) and fractional flow reserve (FFR) into PCI workflow. The approval of the OPTIS Integrated system marks the launch of the world's first PCI optimization system to offer OCT and angiography co-registration, which supports procedural decisions by providing high-resolution, 3-D OCT views of coronary anatomy while mapping the exact location of physician's current view via angiogram. The OPTIS Integrated system also integrates St. Jude Medical PressureWire(TM) fractional flow reserve (FFR) measurement technology to provide access to critical hemodynamic information during PCI. The system will be on display for the first time during Transcatheter Cardiovascular Therapeutics (TCT) 2014, in Washington, D.C. Percutaneous coronary intervention, or coronary angioplasty, is a non-surgical procedure designed to eliminate coronary blood flow blockages and restore blood flow to the heart. Traditionally, physicians have relied on angiography or intravascular ultrasound to guide PCI. St. Jude Medical originally combined OCT and FFR technology in the ILUMIEN(TM) OPTIS and OPTIS Integrated systems to enable a more detailed, physiological and anatomical analysis of blood flow blockages inside the coronary arteries. OPTIS Integrated advances PCI optimization technology further by offering a side-by-side view of OCT and angiography via a co-registration to 'map' culprit lesions and provide the visual data necessary to guide stent selection and deployment. In addition, FFR technology allows physicians to assess the severity of blood flow blockages. Direct tableside controls allow physicians to directly drive system operations while a new user interface prioritizes image display for increased visibility and operation. Stent planning tools enable enhanced precision in determining optimal stent sizing and placement. The benefit of FFR has been supported by a number of clinical trials, including FAME and FAME 2, which demonstrated that St. Jude Medical PressureWire(TM) measurement technology can improve patient outcomes and reduce costs of care in patients with stable coronary artery disease. Primary outcome two-year data from the FAME 2 trial showed that in patients with at least one significant coronary blockage with an FFR value of at least 0.80, FFR-guided PCI plus medical therapy reduced urgent revascularization by 77% compared to medical therapy alone. Two clinical trials -- ILUMIEN I and OPTIMIZE PCI -- are currently underway to further develop the body of clinical evidence supporting OCT technology.

St. Jude Medical Announces Twelve-Month Data from EnligHTN Renal Denervation System

St. Jude Medical Inc. announced 12-month outcome data from the EnligHTN III study, which demonstrated a continuation of safe, rapid and effective treatment with the next-generation EnligHTN(TM) Renal Denervation System for patients with drug-resistant, uncontrolled hypertension. Renal denervation is a specialized ablation procedure that has demonstrated a reduction in blood pressure for patients with hypertension, or high blood pressure, that is resistant to medical therapy. The EnligHTN system delivers radiofrequency (RF) energy from an ablation catheter to create lesions (tiny scars) along the renal nerves -- a network of nerves in the walls of the renal arteries thought to help control blood pressure. The intentional disruption of the nerve supply has been found to help reduce systolic and diastolic blood pressure. The system catheter has a unique, non-occlusive basket design with multiple electrodes, which help physicians deliver a predictable treatment pattern while allowing for continuous blood flow to the kidney throughout the procedure. The next-generation EnligHTN system, CE Mark approved in 2013, delivers simultaneous ablations via a multi-electrode catheter, reducing total ablation time by more than 80% in comparison to the first generation system, from approximately 24 minutes to four minutes. The EnligHTN III study is an international, non-randomized clinical trial that followed device performance and assessed outcomes at six centers through twelve months of follow-up for 37 eligible patients. Twelve-month EnligHTN III data showed an average office systolic blood pressure reduction of 23 mmHg points; an average ambulatory systolic blood pressure reduction of 10 mmHg points; and 78% of patients responded to the therapy, which is defined as a blood pressure reduction of at least 10 mmHg when measured during an office visit.

St. Jude Medical, Inc. Announces Primary Outcome Two-Year Data from the Fame 2 Trial

St. Jude Medical Inc. announced primary outcome two-year data from the FAME 2 Trial which demonstrated sustained superiority with FFR-guided PCI using St. Jude Medical PressureWire(TM) technology in patients with stable coronary artery disease (CAD) compared to standard medical therapy alone. The data were published online in The New England Journal of Medicine (NEJM) and presented during a hot line late-breaking session at the European Society of Cardiology Congress 2014. The results of FAME 2 show patients with stable CAD who received FFR-guided PCI using drug-eluting stents and medical therapy (PCI+MT) had reduced rates of death, myocardial infarction (MI) or urgent revascularization compared to patients who received medical therapy (MT) alone. In particular, in patients who had at least one significant coronary blockage with an FFR value <=0.80, FFR-guided PCI+MT reduced urgent revascularization by 77% compared to medical therapy alone. Specifically, the two year data from FAME 2 shows: Patients who received FFR-guided PCI+MT had a significantly lower rate of death, MI or urgent revascularization than patients who received MT alone (8.1% vs. 19.5%). In a landmark analysis, patients who received FFR-guided PCI+MT had a lower rate of death or MI than patients who received MT alone after seven days (4.6% vs. 8.0%). Patients who received FFR-guided PCI+MT had fewer urgent revascularizations than patients who received MT alone (4.0% vs. 16.3%).


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STJ:US $59.93 USD -0.20

STJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $11.69 USD -0.125
Coloplast A/S kr501.00 DKK +7.00
Smith & Nephew PLC 1,026 GBp -14.00
Terumo Corp ¥2,668 JPY +39.00
Zimmer Holdings Inc $100.31 USD -0.24
View Industry Companies

Industry Analysis


Industry Average

Valuation STJ Industry Range
Price/Earnings 19.4x
Price/Sales 3.1x
Price/Book 4.3x
Price/Cash Flow 18.9x
TEV/Sales 2.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ST JUDE MEDICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at